Search Options Stock News and Analysis from Schaeffer's

2 Pharma Stocks Staging Big Post-Earnings Moves

https://www.schaeffersresearch.com/content/news/2025/05/06/2-pharma-stocks-staging-big-post-earnings-moves

5/6/2025 10:43 AM

Biopharmaceutical giants Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Neurocrine Biosciences Inc (NASDAQ:NBIX) are fresh out of the earnings confessional, with very different results. Vertex saw a...

Buy the Dip on These Biotech Stocks, Say Analysts

https://www.schaeffersresearch.com/content/news/2019/04/22/buy-the-dip-on-these-biotech-stocks-say-analysts

4/22/2019 1:23 PM

Although healthcare stocks just wrapped up a brutal week amid concerns about potential policy shifts in Washington, D.C., analysts are waxing optimistic on a pair of biotech stocks today. More specif...

Cantor Targets 52% Upside for Voyager Therapeutics Stock

https://www.schaeffersresearch.com/content/news/2019/03/06/cantor-targets-52-upside-for-voyager-therapeutics-stock

3/6/2019 9:54 AM

The shares of Voyager Therapeutics Inc (NASDAQ:VYGR) jumped out of the gate, after Cantor Fitzgerald initiated coverage with an "outperform" rating and a $27 price target -- a 52% premium to last nig...

Drug Stock On Track For Best Day Ever After Development Deal

https://www.schaeffersresearch.com/content/news/2019/01/29/drug-stock-on-track-for-best-day-ever-after-development-deal

1/29/2019 9:45 AM

The shares of Voyager Therapeutics Inc (NASDAQ:VYGR) are up 44% to trade at $11.58 this morning, after the gene therapy specialist inked a development deal with Neurocrine Biosciences (NBIX). The deal...

Neurocrine Biosciences Shares Take a Hit on Drug Miss

https://www.schaeffersresearch.com/content/news/2018/12/12/neurocrine-biosciences-shares-take-a-hit-on-drug-miss

12/12/2018 10:52 AM

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) are down 21% at $67.77, after the company said its Tourette's drug failed a mid-stage trial. The dramatic early drop sent NBIX stock to a new an...

PEOPLE ALSO SEARCH FOR